Todd Molfenter1, Dennis McCarty2, Nora Jacobson3, Jee-Seon Kim3, Sanford Starr4, Mark Zehner3. 1. University of Wisconsin-Madison, 1513 University Avenue, Madison, WI 53706, United States of America. Electronic address: todd.molfenter@chess.wisc.edu. 2. Oregon Health & Science University, United States of America. 3. University of Wisconsin-Madison, 1513 University Avenue, Madison, WI 53706, United States of America. 4. Ohio Department of Mental Health and Addiction Services (OhioMHAS), United States of America.
Abstract
BACKGROUND AND OBJECTIVE: County, State, and Federal agencies are addressing the public health opioid crisis. Ohio's 51 county-based Alcohol, Drug Addiction and Mental Health Services (ADAMHS) Boards finance and regulate opioid treatment services within their jurisdictions. This three-year comparative trial collaborated with ADAMHS Boards (n = 14) to test the Advancing Recovery Framework, a suite of organizational and system change strategies designed to promote use of buprenorphine for opioid agonist therapy. METHODS: A multi-level intervention directed payers and treatment agencies to leverage their roles in increasing the use of buprenorphine. Half of the boards partnered with local substance use disorder treatment providers using the partnership strategies recommended by the Advancing Recovery (AR) framework. The comparison boards did not use the partnership strategies. RESULTS AND CONCLUSION: A logistic regression analysis detected increases in the number of patients receiving buprenorphine in both conditions. Buprenorphine use, as a percentage of patients with an opioid use disorder diagnosis, was significantly greater among the boards using the Advancing Recovery strategies during the three-year experimental period (odds ratio (OR) 1.63, 95% CI, 1.50 to 1.76, p < .001) and a one-year maintenance period (OR 2.13, 95% CI, 1.85 to 2.46, p < .001). Boards in both groups provided similar levels of financial support to implement and maintain buprenorphine prescribing. Strategy differences between the study conditions existed in use of a committee that facilitated payer-provider partnering and the ADAMHS boards setting expectations for using buprenorphine. Payer-provider partnerships achieved greater improvements and maximized the effectiveness of funding in increasing access to buprenorphine. Published by Elsevier Inc.
RCT Entities:
BACKGROUND AND OBJECTIVE: County, State, and Federal agencies are addressing the public health opioid crisis. Ohio's 51 county-based Alcohol, Drug Addiction and Mental Health Services (ADAMHS) Boards finance and regulate opioid treatment services within their jurisdictions. This three-year comparative trial collaborated with ADAMHS Boards (n = 14) to test the Advancing Recovery Framework, a suite of organizational and system change strategies designed to promote use of buprenorphine for opioid agonist therapy. METHODS: A multi-level intervention directed payers and treatment agencies to leverage their roles in increasing the use of buprenorphine. Half of the boards partnered with local substance use disorder treatment providers using the partnership strategies recommended by the Advancing Recovery (AR) framework. The comparison boards did not use the partnership strategies. RESULTS AND CONCLUSION: A logistic regression analysis detected increases in the number of patients receiving buprenorphine in both conditions. Buprenorphine use, as a percentage of patients with an opioid use disorder diagnosis, was significantly greater among the boards using the Advancing Recovery strategies during the three-year experimental period (odds ratio (OR) 1.63, 95% CI, 1.50 to 1.76, p < .001) and a one-year maintenance period (OR 2.13, 95% CI, 1.85 to 2.46, p < .001). Boards in both groups provided similar levels of financial support to implement and maintain buprenorphine prescribing. Strategy differences between the study conditions existed in use of a committee that facilitated payer-provider partnering and the ADAMHS boards setting expectations for using buprenorphine. Payer-provider partnerships achieved greater improvements and maximized the effectiveness of funding in increasing access to buprenorphine. Published by Elsevier Inc.
Authors: Laura A Schmidt; Traci Rieckmann; Amanda Abraham; Todd Molfenter; Victor Capoccia; Paul Roman; David H Gustafson; Dennis McCarty Journal: J Stud Alcohol Drugs Date: 2012-05 Impact factor: 2.582
Authors: Chris-Ellyn Johanson; Cynthia L Arfken; Salvatore di Menza; Charles Roberts Schuster Journal: Drug Alcohol Depend Date: 2011-08-21 Impact factor: 4.492
Authors: Erin L Winstanley; Joe Gay; Lisa Roberts; Judi Moseley; Orman Hall; B Christine Beeghly; Theresa Winhusen; Eugene Somoza Journal: Public Health Nurs Date: 2012-08-26 Impact factor: 1.462
Authors: Dennis McCarty; David H Gustafson; Jennifer P Wisdom; Jay Ford; Dongseok Choi; Todd Molfenter; Victor Capoccia; Frances Cotter Journal: Drug Alcohol Depend Date: 2006-11-28 Impact factor: 4.492
Authors: Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn Journal: JAMA Netw Open Date: 2020-02-05
Authors: James H Ford; Arveen Kaur; Deepika Rao; Aaron Gilson; Daniel M Bolt; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern Journal: Implement Res Pract Date: 2021-09-17
Authors: Margarita Alegría; Irene Falgas-Bague; Marie Fukuda; Jenny Zhen-Duan; Cole Weaver; Isabel O'Malley; Timothy Layton; Jacob Wallace; Lulu Zhang; Sheri Markle; Charles Neighbors; Pat Lincourt; Shazia Hussain; Marc Manseau; Bradley D Stein; Nancy Rigotti; Sarah Wakeman; Martha Kane; A Eden Evins; Thomas McGuire Journal: JAMA Health Forum Date: 2022-07-01
Authors: James H Ford; Deepika Rao; Aaron Gilson; Arveen Kaur; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern Journal: J Dual Diagn Date: 2022-04-07